AI Article Synopsis

  • The study investigates the role of the TRAIL receptor in a mouse model of chronic cholestatic liver disease.
  • Researchers found that mice lacking the TRAIL receptor experienced more severe liver damage, increased fibrosis, and a greater number of ductular reactive (DR) cells compared to normal mice.
  • The findings suggest that the absence of the TRAIL receptor leads to changes in cell death and increases inflammation in the liver, highlighting its potential role in liver disease progression.

Article Abstract

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL; TNFSF10) receptor (TR) is a pro-apoptotic receptor whose contribution to chronic cholestatic liver disease is unclear. Herein, we examined TRAIL receptor signaling in a mouse model of cholestatic liver injury. TRAIL receptor-deficient (Tnsf10 or Tr) mice were crossbred with ATP binding cassette subfamily B member 4-deficient (Abcb4, alias Mdr2) mice. Male and female wild-type, Tr, Mdr2, and TrMdr2 mice were assessed for liver injury, fibrosis, and ductular reactive (DR) cells. Macrophage subsets were examined by high-dimensional mass cytometry (time-of-flight mass cytometry). Mdr2 and TrMdr2 mice had elevated liver weights and serum alanine transferase values. However, fibrosis was primarily periductular in Mdr2 mice, compared with extensive bridging fibrosis in TrMdr2 mice. DR cell population was greatly expanded in the TrMdr2 versus Mdr2 mice. The expanded DR cell population in TrMdr2 mice was due to decreased cell loss by apoptosis and not enhanced proliferation. As assessed by time-of-flight mass cytometry, total macrophages were more abundant in TrMdr2 versus Mdr2 mice, suggesting the DR cell population promotes macrophage-associated hepatic inflammation. Inhibition of monocyte-derived recruited macrophages using the CCR2/CCR5 antagonist cenicriviroc in the Mdr2 mice resulted in further expansion of the DR cell population. In conclusion, genetic deletion of TRAIL receptor increased the DR cell population, macrophage accumulation, and hepatic fibrosis in the Mdr2 model of cholestasis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280758PMC
http://dx.doi.org/10.1016/j.ajpath.2020.02.013DOI Listing

Publication Analysis

Top Keywords

mdr2 mice
20
cell population
20
trmdr2 mice
16
mass cytometry
12
mice
10
tumor necrosis
8
necrosis factor-related
8
factor-related apoptosis-inducing
8
apoptosis-inducing ligand
8
macrophage accumulation
8

Similar Publications

[Study on the mechanism of Fuzheng Huayu formula against biliary fibrosis in mice].

Zhonghua Gan Zang Bing Za Zhi

November 2024

Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai201203, China Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai Key Laboratory of Traditional Chinese Medicine, Shanghai201203, China.

Article Synopsis
  • The study aimed to explore how the Fuzheng huayu formula (FZHY) affects biliary fibrosis in mice by comparing its effects with obeticholic acid (OCA) and a control group.
  • Mice were treated with specific drugs over a 12-week period, and various liver health indicators, including serum enzyme levels and tissue markers, were analyzed using multiple biochemical techniques.
  • Results demonstrated that both FZHY and OCA effectively reduced the harmful effects of fibrosis in the gene knockout mice by reversing elevated liver indicators, improving markers of liver function, and influencing specific molecular pathways related to inflammation and cellular response.
View Article and Find Full Text PDF

Background: Fibroinflammatory cholangiopathies, such as primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), are characterized by inflammation and biliary fibrosis, driving disease-related complications. In biliary fibrosis, cholangiocytes activated by transforming growth factor-β (TGFβ) release signals that recruit immune cells to drive inflammation and activate hepatic myofibroblasts to deposit the extracellular matrix (ECM). TGFβ regulates stearoyl-CoA desaturase (SCD), an enzyme that catalyzes the synthesis of monounsaturated fatty acids, in stimulating fibroinflammatory lipid signaling.

View Article and Find Full Text PDF
Article Synopsis
  • - Cholangiopathies are complex disorders with limited understanding and no effective treatments, prompting a study on the extrahepatic biliary tree (EHBD) in Mdr2 mice, a cholestatic mouse model, across different ages (2 to 40 weeks).
  • - The study assessed the effects of N-acetyl-L-Cysteine (NAC), an antioxidant and glutathione precursor, on EHBD injury both ex vivo (using bile duct samples) and in vivo (through oral administration for three weeks).
  • - Results showed that NAC treatment improved bile duct morphology and reduced liver fibrosis along with lower liver enzyme levels, suggesting a shift in cellular state from apoptosis to proliferation, indicating NAC's potential as a therapeutic
View Article and Find Full Text PDF

Serum metabonomics reveal the effectiveness of human placental mesenchymal stem cell therapy for primary sclerosing cholangitis.

Stem Cell Res Ther

October 2024

State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou City, 310003, China.

Article Synopsis
  • The study looks at how a type of stem cell treatment from the placenta can help patients with a liver disease called primary sclerosing cholangitis (PSC).
  • Researchers used special mice to see how the stem cell treatment affected their liver health and identified important substances in their blood to check its effectiveness.
  • They found that after the treatment, certain harmful substances in the liver decreased while beneficial ones increased, suggesting the stem cell treatment was successful in improving liver function.
View Article and Find Full Text PDF

Liver fibrosis associated with increased mortality is caused by activation of hepatic stellate cells and excessive production and accumulation of extracellular matrix in response to fibrotic insults. It has been shown that in addition to liver inflammation, systemic inflammation also contributes to liver fibrogenesis. A deeper understanding of mechanisms that control liver fibrotic response to intra- and extra-hepatic inflammation is essential to develop novel clinical strategies against this disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!